Literature DB >> 33144339

Setting the Pick: Can PI3K Inhibitors Circumvent CDK4/6 Inhibitor Resistance?

Amy S Clark1,2, Igor Makhlin3,2, Angela DeMichele3,2.   

Abstract

PI3K and CDK4/6 inhibitors (CDK4/6i) are targeted therapies approved to treat advanced breast cancer; CDK4/6is are more widely used. Here, we discuss trials that examine PI3K inhibitors with novel drug combinations, including a CDK4/6i, given data implicating the pathway in CDK 4/6 resistance.See related articles by Lu et al., p. 408, and Tolaney et al., p. 418. ©2020 American Association for Cancer Research.

Entities:  

Year:  2020        PMID： 33144339      PMCID： PMC8278622          DOI： 10.1158/1078-0432.CCR-20-3624

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  8 in total

1.  A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.

Authors:  Yen-Shen Lu; Keun Seok Lee; Tsu-Yi Chao; Ling-Ming Tseng; Imjai Chitapanarux; Shin-Cheh Chen; Chien-Ting Liu; Joohyuk Sohn; Jee Hyun Kim; Yuan-Ching Chang; Youngsen Yang; Kanjana Shotelersuk; Kyung Hae Jung; Roberta Valenti; Cassandra Slader; Melissa Gao; Yeon Hee Park
Journal:  Clin Cancer Res       Date:  2020-07-27       Impact factor: 12.531

2.  Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer.

Authors:  Sara M Tolaney; Young-Hyuck Im; Emiliano Calvo; Yen-Shen Lu; Erika Hamilton; Andres Forero-Torres; Thomas Bachelot; Michela Maur; Angelica Fasolo; Ralph Tiedt; Lisa Nardi; Uz Stammberger; Ahmed M Abdelhady; Shiling Ruan; Soo Chin Lee
Journal:  Clin Cancer Res       Date:  2020-09-04       Impact factor: 12.531

3.  CDK4/6 Inhibition in Breast Cancer: Mechanisms of Response and Treatment Failure.

Authors:  Ana C Garrido-Castro; Shom Goel
Journal:  Curr Breast Cancer Rep       Date:  2017-02-01

4.  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.

Authors:  Debu Tripathy; Seock-Ah Im; Marco Colleoni; Fabio Franke; Aditya Bardia; Nadia Harbeck; Sara A Hurvitz; Louis Chow; Joohyuk Sohn; Keun Seok Lee; Saul Campos-Gomez; Rafael Villanueva Vazquez; Kyung Hae Jung; K Govind Babu; Paul Wheatley-Price; Michelino De Laurentiis; Young-Hyuck Im; Sherko Kuemmel; Nagi El-Saghir; Mei-Ching Liu; Gary Carlson; Gareth Hughes; Ivan Diaz-Padilla; Caroline Germa; Samit Hirawat; Yen-Shen Lu
Journal:  Lancet Oncol       Date:  2018-05-24       Impact factor: 41.316

5.  Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.

Authors:  Seock-Ah Im; Yen-Shen Lu; Aditya Bardia; Nadia Harbeck; Marco Colleoni; Fabio Franke; Louis Chow; Joohyuk Sohn; Keun-Seok Lee; Saul Campos-Gomez; Rafael Villanueva-Vazquez; Kyung-Hae Jung; Arunava Chakravartty; Gareth Hughes; Ioannis Gounaris; Karen Rodriguez-Lorenc; Tetiana Taran; Sara Hurvitz; Debu Tripathy
Journal:  N Engl J Med       Date:  2019-06-04       Impact factor: 91.245

6.  Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Fabrice André; Eva Ciruelos; Gabor Rubovszky; Mario Campone; Sibylle Loibl; Hope S Rugo; Hiroji Iwata; Pierfranco Conte; Ingrid A Mayer; Bella Kaufman; Toshinari Yamashita; Yen-Shen Lu; Kenichi Inoue; Masato Takahashi; Zsuzsanna Pápai; Anne-Sophie Longin; David Mills; Celine Wilke; Samit Hirawat; Dejan Juric
Journal:  N Engl J Med       Date:  2019-05-16       Impact factor: 91.245

7.  Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor-Positive Breast Cancer.

Authors:  Maria Teresa Herrera-Abreu; Marta Palafox; Uzma Asghar; Martín A Rivas; Rosalind J Cutts; Isaac Garcia-Murillas; Alex Pearson; Marta Guzman; Olga Rodriguez; Judit Grueso; Meritxell Bellet; Javier Cortés; Richard Elliott; Sunil Pancholi; José Baselga; Mitch Dowsett; Lesley-Ann Martin; Nicholas C Turner; Violeta Serra
Journal:  Cancer Res       Date:  2016-03-28       Impact factor: 12.701

8.  Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer.

Authors:  Neil A O'Brien; Martina S J McDermott; Dylan Conklin; Tong Luo; Raul Ayala; Suruchi Salgar; Kevin Chau; Emmanuelle DiTomaso; Naveen Babbar; Faye Su; Alex Gaither; Sara A Hurvitz; Ronald Linnartz; Kristine Rose; Samit Hirawat; Dennis J Slamon
Journal:  Breast Cancer Res       Date:  2020-08-14       Impact factor: 6.466
  8 in total
  2 in total

1.  Clinical management of metastatic hormone receptor-positive, HER2-negative breast cancer (MBC) after CDK 4/6 inhibitors: a retrospective single-institution study.

Authors:  Grace M Choong; Savannah Liddell; Roberto A Leon Ferre; Ciara C O'Sullivan; Kathryn J Ruddy; Tufia C Haddad; Timothy J Hobday; Prema P Peethambaram; Minetta C Liu; Matthew P Goetz; Karthik V Giridhar
Journal:  Breast Cancer Res Treat       Date:  2022-08-31       Impact factor: 4.624

Review 2.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.